Off-Label GLP-1 Use Skyrockets in Young Kids
Saturday, September 5 – (MedPage Today) — Prescribing GLP-1 receptor agonists to children ages 8 to 11 years with obesity surged 310-fold since 2019, despite a lack of FDA approval in kids under 12, a large cross-sectional analysis showed.
Among over 3.5 million children…
GLP-1 use among young children with obesity in US remains rare but is rising rapidly
Saturday, September 5 – Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first prescribed, a new study shows.
GLP-1 Scripts Rising Faster Among Adults With Serious Mental Illness
Saturday, September 5 – (MedPage Today) — Adults with serious mental illness (SMI) received GLP-1 drug prescriptions at higher rates than those without SMI from 2018 to 2024, an analysis of U.S. insurance claims data showed.
Among people with an underlying GLP-1-indicating…
Regulatory: Nods for Mounjaro in lowering CV risk, Bixlenvo and Tivicay in HIV
Saturday, September 5 – Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbott, Abbvie, Alvotech, Astrazeneca, Beyond, Biogen, Biontech, Bonesupport, Cortec, Cytomx, Daiichi Sankyo, Eisai, Eli Lilly, GE, Gilead, Hamamatsu, Highlife, Hutchmed, Juniper, Karyopharm, Kowa, Moderna, Nicox, Novavax, Palvella, Pfizer, Pharmassentia, Pixcell, Priovant, Revolution, Roche, Ropca, Scholar Rock, SL, Takeda, T-Maximum, Uniqure, United, Vara, Viiv, Xentria, Zambon.
FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes
Thursday, September 3 – The FDA has approved Mounjaro for cardiovascular risk reduction in people with type 2 diabetes. Milko · E+/Getty
The FDA has approved Mounjaro to help reduce the risk of major cardiovascular events in people with type 2 diabetes who are at high risk.
A major clinical trial found that Mounjaro performed as well as Trulicity for reducing the risk of heart attack, stroke, and cardiovascular death.
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
Thursday, September 3 – Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on understanding disease biology and selecting the right drug candidates to derisk clinical trials.
Leslie Mann Revealed Why Judd Apatow Has Actually Gained Weight On Ozempic, And People Are Perplexed
Wednesday, September 2 – “He’s on the highest dose, and he likes to outrun the feeling that…Ozempic gives you to stop eating.”View Entire Post ›
As GLP-1 Use Expands Into Dermatology, So Do the Medicolegal Implications
Wednesday, September 2 – (MedPage Today) — Medical liability cases involving GLP-1 receptor agonist use in dermatology have occurred infrequently to date but warrant careful attention as the use increases, a medicolegal review suggests.
A review of the LexisNexis legal…
Mounjaro’s Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib
Wednesday, September 2 – (MedPage Today) — The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes, Eli Lilly announced.
Global type 1 diabetes prevalence…
GLP-1 RAs produce significant weight loss in adults without diabetes, with newer treatments showing greater results
Wednesday, September 2 – An updated systematic review evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and coagonists among adults with overweight or obesity without diabetes found that, among currently available treatments, tirzepatide produced the greatest weight loss, while newer experimental drugs showed even larger effects.